EGFR and neoplasm: But after literatures investigation about the optimal timing of immunotherapy [34, 35] and the potential impact of EGFR-TKI on tumor microenvironment [36, 37], we prone to believe that the earlier treatment of immunochemotherapy after EGFR-TKI resistance, the better therapeutic effect would be observed.